Pathway-based personalized analysis of breast cancer expression data

Molecular Oncology

Volumn 9, Issue 7, 2015, Pages 1471-1483

  Livshits, Anna ^a   Git, Anna ^b,c   Fuks, Garold ^a   Caldas, Carlos ^b,c   Domany, Eytan ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Breast cancer; Pathway based analysis; PKA pathways

Indexed keywords

ARTICLE; BREAST CANCER; CONTROLLED STUDY; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; PATHWAY DEREGULATION SCORE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PRKACB GENE; SCORING SYSTEM; TUMOR ASSOCIATED LEUKOCYTE; BREAST TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENETICS; PROTO ONCOGENE; REPRODUCIBILITY; VALIDATION STUDY;

ESTROGEN RECEPTOR;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENES, ERBB-2; HUMANS; PRECISION MEDICINE; RECEPTORS, ESTROGEN; REPRODUCIBILITY OF RESULTS;

EID: 84938201089     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2015.04.006     Document Type: Article

References (42)

1. Alexe G., Dalgin G.S., Ramaswamy R., DeLisi C., Bhanot G. Data perturbation independent diagnosis and validation of breast cancer subtypes using clustering and patterns. Cancer Inform. 2006, 2:243-274.
2. Alexe G., Dalgin G.S., Scanfeld D., Tamayo P., Mesirov J.P., DeLisi C., Harris L., Barnard N., Martel M., Levine A.J., Ganesan S., Bhanot G. High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res. 2007, 67:10669-10676.
3. Ali H.R., Provenzano E., Dawson S.J., Blows F.M., Liu B., Shah M., Earl H.M., Poole C.J., Hiller L., Dunn J.A., Bowden S.J., Twelves C., Bartlett J.M.S., Mahmoud S.M.A., Rakha E., Ellis I.O., Liu S., Gao D., Nielsen T.O., Pharoah P.D.P., Caldas C. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann. Oncol. 2014, 25:1536-1543.
4. Benjamini Y., Hochberg Y. Controlling the false discovery rate - a practical and powerful approach to multiple testing. J. Roy Stat. Soc. B 1995, 57:289-300.
5. Beuschlein F., Fassnacht M., Assie G., Calebiro D., Stratakis C.A., Osswald A., Ronchi C.L., Wieland T., Sbiera S., Faucz F.R., Schaak K., Schmittfull A., Schwarzmayr T., Barreau O., Vezzosi D., Rizk-Rabin M., Zabel U., Szarek E., Salpea P., Forlino A., Vetro A., Zuffardi O., Kisker C., Diener S., Meitinger T., Lohse M.J., Reincke M., Bertherat J., Strom T.M., Allolio B. Constitutive activation of PKA catalytic subunit in adrenal Cushing's syndrome. New Engl. J. Med. 2014, 370:1019-1028.
6. Bilal E., Dutkowski J., Guinney J., Jang I.S., Logsdon B.A., Pandey G., Sauerwine B.A., Shimoni Y., Moen Vollan H.K., Mecham B.H., Rueda O.M., Tost J., Curtis C., Alvarez M.J., Kristensen V.N., Aparicio S., Borresen-Dale A.L., Caldas C., Califano A., Friend S.H., Ideker T., Schadt E.E., Stolovitzky G.A., Margolin A.A. Improving breast cancer survival analysis through competition-based multidimensional modeling. PLoS Comput. Biol. 2013, 9:e1003047.
7. Bustin S.A., Benes V., Garson J.A., Hellemans J., Huggett J., Kubista M., Mueller R., Nolan T., Pfaffl M.W., Shipley G.L., Vandesompele J., Wittwer C.T. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 2009, 55:611-622.
8. Calabrò A., Beissbarth T., Kuner R., Stojanov M., Benner A., Asslaber M., Ploner F., Zatloukal K., Samonigg H., Poustka A., Sültmann H. Effects of infiltrating lymphocytes and estrogen receptor on gene expression and prognosis in breast cancer. Breast Cancer Res. Treat. 2009, 116:69-77.
9. Curtis C., Shah S.P., Chin S.F., Turashvili G., Rueda O.M., Dunning M.J., Speed D., Lynch A.G., Samarajiwa S., Yuan Y., Graf S., Ha G., Haffari G., Bashashati A., Russell R., McKinney S., Langerod A., Green A., Provenzano E., Wishart G., Pinder S., Watson P., Markowetz F., Murphy L., Ellis I., Purushotham A., Borresen-Dale A.L., Brenton J.D., Tavare S., Caldas C., Aparicio S. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486:346-352.
10. DeSantis C., Siegel R., Bandi P., Jemal A. Breast cancer statistics, 2011. CA Cancer J. Clini. 2011, 61:408-418.
11. Drier Y., Sheffer M., Domany E. Pathway-based personalized analysis of cancer. Proc. Natl. Acad. Sci. USA 2013, 110:6388-6393.
12. Foley J., Nickerson N.K., Nam S., Allen K.T., Gilmore J.L., Nephew K.P., Riese Ii D.J. EGFR signaling in breast cancer: bad to the bone. Semin. Cell Dev. Biol. 2010, 21:951-960.
13. Forlino A., Vetro A., Garavelli L., Ciccone R., London E., Stratakis C.A., Zuffardi O. PRKACB and Carney complex. New Engl. J. Med. 2014, 370:1065-1067.
14. Francis S.H., Blount M.A., Corbin J.D. Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol. Rev. 2011, 91:651-690.
15. Furuta K., Arao T., Sakai K., Kimura H., Nagai T., Tamura D., Aomatsu K., Kudo K., Kaneda H., Fujita Y., Matsumoto K., Yamada Y., Yanagihara K., Sekijima M., Nishio K. Integrated analysis of whole genome exon array and array-comparative genomic hybridization in gastric and colorectal cancer cells. Cancer Sci. 2012, 103:221-227.
16. Geiger T., Madden S.F., Gallagher W.M., Cox J., Mann M. Proteomic portrait of human breast cancer progression identifies novel prognostic markers. Cancer Res. 2012, 72:2428-2439.
17. Haibe-Kains B., Desmedt C., Loi S., Culhane A.C., Bontempi G., Quackenbush J., Sotiriou C. A three-gene model to robustly identify breast cancer molecular subtypes. J. Natl. Cancer Inst. 2012, 104:311-325.
18. Hastie T., Stuetzle W. Principal curves. J. Am. Stat. Assoc. 1989, 84:502-516.
19. Huang S., Yee C., Ching T., Yu H., Garmire L.X. A novel model to combine clinical and pathway-based transcriptomic information for the prognosis prediction of breast cancer. PLoS Comput. Biol. 2014, 10:e1003851.
20. Ideker T., Dutkowski J., Hood L. Boosting signal-to-noise in complex biology: prior knowledge is power. Cell 2011, 144:860-863.
21. Johnson D.A., Akamine P., Radzio-Andzelm E., Madhusudan M., Taylor S.S. Dynamics of cAMP-dependent protein kinase. Chem. Rev. 2001, 101:2243-2270.
22. Kanehisa M., Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000, 28:27-30.
23. Kanehisa M., Goto S., Furumichi M., Tanabe M., Hirakawa M. KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res. 2010, 38:D355-D360.
24. Loi S., Sirtaine N., Piette F., Salgado R., Viale G., Van Eenoo F., Rouas G., Francis P., Crown J.P., Hitre E., de Azambuja E., Quinaux E., Di Leo A., Michiels S., Piccart M.J., Sotiriou C. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J. Clin. Oncol. 2013, 31:860-867.
25. Nishimura D. BioCarta. Biotech. Softw. Internet Rep. 2001, 2:117-120.
26. Parker J.S., Mullins M., Cheang M.C., Leung S., Voduc D., Vickery T., Davies S., Fauron C., He X., Hu Z., Quackenbush J.F., Stijleman I.J., Palazzo J., Marron J.S., Nobel A.B., Mardis E., Nielsen T.O., Ellis M.J., Perou C.M., Bernard P.S. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 2009, 27:1160-1167.
27. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., Fluge O., Pergamenschikov A., Williams C., Zhu S.X., Lonning P.E., Borresen-Dale A.L., Brown P.O., Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
28. Polyak K. Heterogeneity in breast cancer. J. Clin. Invest. 2011, 121:3786-3788.
29. Rody A., Holtrich U., Pusztai L., Liedtke C., Gaetje R., Ruckhaeberle E., Solbach C., Hanker L., Ahr A., Metzler D., Engels K., Karn T., Kaufmann M. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res. 2009, 11:R15.
30. Schaefer C.F., Anthony K., Krupa S., Buchoff J., Day M., Hannay T., Buetow K.H. PID: the pathway interaction database. Nucleic Acids Res. 2009, 37:D674-D679.
31. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Thorsen T., Quist H., Matese J.C., Brown P.O., Botstein D., Lonning P.E., Borresen-Dale A.L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 2001, 98:10869-10874.
32. Sotiriou C., Pusztai L. Gene-expression signatures in breast cancer. New Engl. J. Med. 2009, 360:790-800.
33. Soubeyran P., Kowanetz K., Szymkiewicz I., Langdon W.Y., Dikic I. Cbl-CIN85-endophilin complex mediates ligand-induced downregulation of EGF receptors. Nature 2002, 416:183-187.
34. TCGA Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70.
35. Teschendorff A., Miremadi A., Pinder S., Ellis I., Caldas C. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol. 2007, 8:R157.
36. Tsafrir D., Tsafrir I., Ein-Dor L., Zuk O., Notterman D.A., Domany E. Sorting points into neighborhoods (SPIN): data analysis and visualization by ordering distance matrices. Bioinformatics 2005, 21:2301-2308.
37. van 't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., Peterse H.L., van der Kooy K., Marton M.J., Witteveen A.T., Schreiber G.J., Kerkhoven R.M., Roberts C., Linsley P.S., Bernards R., Friend S.H. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
38. van der Vegt B., de Bock G.H., Hollema H., Wesseling J. Microarray methods to identify factors determining breast cancer progression: potentials, limitations, and challenges. Crit. Rev. Oncol. Hematol. 2009, 70:1-11.
39. Vaske C.J., Benz S.C., Sanborn J.Z., Earl D., Szeto C., Zhu J., Haussler D., Stuart J.M. Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics 2010, 26:i237-245.
40. Verhaegh W., Van de Stolpe A. Knowledge-based computational models. Oncotarget 2014, 5:5196-5197.
41. Verhaegh W., van Ooijen H., Inda M.A., Hatzis P., Versteeg R., Smid M., Martens J., Foekens J., van de Wiel P., Clevers H., van de Stolpe A. Selection of personalized patient therapy through the use of knowledge-based computational models that identify tumor-driving signal transduction pathways. Cancer Res. 2014, 74:2936-2945.
42. Wang Y., Klijn J.G., Zhang Y., Sieuwerts A.M., Look M.P., Yang F., Talantov D., Timmermans M., Meijer-van Gelder M.E., Yu J., Jatkoe T., Berns E.M., Atkins D., Foekens J.A. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365:671-679.